Slide 1: Q2’25 Earnings Presentation
NASDAQ: HBIO Q2’25 Earnings Presentation John Duke, President & CEO Mark Frost, Interim CFO & Treasurer August 11, 2025
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified
Slide 3: Q2’25 Highlights
Q2’25 Highlights Delivered results above expectations, continue to focus on cost management Income Statement Components ($ in millions except percentages) Q2 2025 Q2 2024 Revenue 20.5 23.1 Gross Margin 11.5 13.2 % of Revenue 56.4% 57.2% Operating Loss (0.8) (2.1) % of Revenue -4.0% -9.0% Adjusted Op
Slide 4: Quarterly Product Revenue by Region
Quarterly Product Revenue by Region Pre-clinical CMT Americas EMEA APAC NIH/ACA funding uncertainty drive US Pre- EMEA relatively flat driven by APAC decrease driven by China tariffs Clinical declines, CMT stabilizes macroeconomic instability • Overall: Q2 9.3% sequential increase, • Overall: Q2 25.
Slide 5: Q2’25 Financial Metrics (GAAP except where noted)
Q2’25 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $1.5 $13.2 $1.3 $11.5 EARNINGS (LOSS) PER SHARE YTD CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* Q2’25 Q2’24 Q2’25 Q2’24 * Non-GAAP measure, see Slide 10 for reconciliation t
Slide 6: Outlook
Outlook 6
Slide 7: Q3 2025 Outlook
Q3 2025 Outlook Our third quarter guidance shows stability and financial discipline: ▪ Q3 Revenues ranging from $19M to $21M ▪ Q3 Gross Margin ranging from 56-58% Near-term headwinds persist but fundamentals remain intact as we prioritize broader adoption of our new products while maintaining strict
Slide 8: Second Quarter Operating & Financial Summary
Second Quarter Operating & Financial Summary ▪ Key priorities for the remainder of 2025: ▪ Maintaining financial discipline by continuing to deliver cost efficiencies and generate positive cash flow ▪ Accelerating product adoption by leveraging our strong and innovative pipeline to position the comp
Slide 9: Appendix
Appendix 9
Slide 10: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses for the three months ended June 30, 2025 includes $30 thousand of restructuring-related charges and $170 thousand of employee retention tax credit fees compared to $396 thousand of restructuring expenses and a credit of $145 thousand of unclaim
Slide 11: New Product Introductions: Supports Long Term Growth Targets
New Product Introductions: Supports Long Term Growth Targets Growth Category New Product Introductions 2024 Achievements 2025 Goals/Achievements • Expand telemetry endpoints to include cardiac and neuro • SoHo (Shared Housing) • First shipments for temperature and • Launched commercially at March’s
Slide 12: Confidential & Proprietary Information
Confidential & Proprietary Information 12